🇺🇸 bortezomib + rituximab in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Acute Kidney Injury — 2 reports (15.38%)
  2. Chronic Kidney Disease — 2 reports (15.38%)
  3. Renal Failure — 2 reports (15.38%)
  4. Abdominal Pain — 1 report (7.69%)
  5. Anaphylactic Reaction — 1 report (7.69%)
  6. Arthralgia — 1 report (7.69%)
  7. Asthenia — 1 report (7.69%)
  8. Covid-19 — 1 report (7.69%)
  9. Cytokine Release Syndrome — 1 report (7.69%)
  10. Decreased Appetite — 1 report (7.69%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is bortezomib + rituximab approved in United States?

bortezomib + rituximab does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for bortezomib + rituximab in United States?

Jonsson Comprehensive Cancer Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.